SCHEMBL24258741

SCHEMBL24258741

COC(=O)CCCCc1ccnc(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.42
MIF P14174 1/20 0.40
TSHR P16473 1/20 0.39
JAK2 O60674 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
P2RY12 Q9H244 1/20 0.39
LTB4R Q15722 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CNR2 P34972 1/20 0.38
KAT2B Q92831 2/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15820785 0.82 TNF (0.43) SMN1; SMN2MAPTTDP1
SCHEMBL17618001 0.80 ALDH1A1 (0.45) HPGDALDH1A1SMN1; SMN2MAPTABL1
SCHEMBL22610223 0.75 HPGD (0.45) HPGDALDH1A1SMN1; SMN2MAPTMIF
SCHEMBL7676108 0.75 CYP4F2 (0.45) ALDH1A1MAPTL3MBTL1
SCHEMBL27667823 0.75 KCNH2 (0.42) ALDH1A1SMN1; SMN2L3MBTL1CNR2
SCHEMBL4301655 0.75 KCNH2 (0.53) MIFL3MBTL1TDP1CNR2
SCHEMBL7229458 0.75 MAPT (0.41) ALDH1A1SMN1; SMN2MAPTTSHRLTB4R
SCHEMBL5245682 0.74 SUCNR1 (0.53) ALDH1A1SMN1; SMN2
SCHEMBL6643882 0.74 SMN1; SMN2 (0.55) HPGDALDH1A1SMN1; SMN2HDAC6LTB4R
SCHEMBL24259216 0.74 KMT2A (0.47) HPGDALDH1A1MAPTMIFTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-05-05 US disclosed
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135550-A1 SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS FXR1, NR1H4, FXR2 HPGD 962/4885ALDH1A1 2862/4885SMN1; SMN2 4733/4885
US-11254663-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 HPGD 962/4885ALDH1A1 2862/4885SMN1; SMN2 4733/4885
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators FXR1, NR1H4, FXR2 HPGD 962/4885ALDH1A1 2862/4885SMN1; SMN2 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.